內部人交易

EDGAR

Evoke Pharma Inc

董事、高階主管與持股10%以上股東在SEC表格3、4、5中申報的交易,讀取自每份申報文件的XML。代碼及其措辭均為SEC原文。

表格4須於交易後兩個工作日內提交,因此最近的交易可能尚未申報。

範圍:日期在2025年11月16日或之後的交易。

公開市場買進(代碼P)
0筆交易,—股
公開市場賣出(代碼S)
0筆交易,—股

合計為所列已申報交易之和;它們統計的是已申報的內容,並不表示方向。

顯示第1–37項,共37項

內部人交易,最新在前,依SEC表格3、4、5申報
日期申報人代碼取得或處分股數每股價格(依申報)價值(推算)交易後持股直接或間接規則10b5-1勾選框註腳來源
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
處分(D)148,15311.00
1,629,683

推算:股數 × 每股價格。精確值 1629683.00。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生證券: Prefunded Warrants — 標的 Common Stock (433,962) — 行使價 0.0001
處分(D)433,96210.999
4,773,148.038

推算:股數 × 每股價格。精確值 4773148.038。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生證券: Series A Common Stock Purchase Warrants — 標的 Common Stock (117,019) — 行使價 8.16
處分(D)117,0194.71
551,159.49

推算:股數 × 每股價格。精確值 551159.49。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生證券: Series C Common Stock Purchase Warrants — 標的 Common Stock (117,019) — 行使價 8.16
處分(D)117,0194.71
551,159.49

推算:股數 × 每股價格。精確值 551159.49。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生證券: Amended Series A Common Stock Purchase Warrants — 標的 Common Stock (158,531) — 行使價 0.01
處分(D)158,53110.99
1,742,255.69

推算:股數 × 每股價格。精確值 1742255.69。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生證券: Amended Series C Common Stock Purchase Warrants — 標的 Common Stock (250,627) — 行使價 0.01
處分(D)250,62710.99
2,754,390.73

推算:股數 × 每股價格。精確值 2754390.73。

0間接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
開啟申報文件 0001104659-25-123156 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,218) — 行使價 5.41
處分(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322642 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 4.45
處分(D)5,833——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322642 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,218) — 行使價 3.453
處分(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322642 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,479) — 行使價 5.41
處分(D)1,479——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322643 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (8,750) — 行使價 4.45
處分(D)8,750——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322643 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,291) — 行使價 3.453
處分(D)1,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322643 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,187) — 行使價 5.41
處分(D)1,187——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322641 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 4.45
處分(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322641 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,187) — 行使價 3.453
處分(D)1,187——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322641 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,250) — 行使價 5.41
處分(D)1,250——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322638 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 4.45
處分(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322638 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,250) — 行使價 3.453
處分(D)1,250——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322638 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,218) — 行使價 5.41
處分(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322639 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 4.45
處分(D)5,833——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322639 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,187) — 行使價 3.453
處分(D)1,187——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322639 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 5.51
處分(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322645 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,125) — 行使價 3.453
處分(D)1,125——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322645 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (17,291) — 行使價 5.27
處分(D)17,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322644 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (11,000) — 行使價 4.45
處分(D)11,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322644 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (64,840) — 行使價 5.27
處分(D)64,840——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322637 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (70,000) — 行使價 4.45
處分(D)70,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322637 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (17,291) — 行使價 5.27
處分(D)17,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322640 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (13,000) — 行使價 4.45
處分(D)13,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322640 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (5,833) — 行使價 5.26
處分(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322646 讀取自申報文件的XML 對此列提出異議
2025年12月17日 申報日期:2025年12月17日PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生證券: Stock Option (Right to Buy) — 標的 Common Stock (1,155) — 行使價 3.453
處分(D)1,155——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
開啟申報文件 0001193125-25-322646 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)133——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322642 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)2,330——0間接(I) By Garner Investments, L.L.C.否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322643 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)27——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322639 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)360——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322644 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)15,509——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322637 讀取自申報文件的XML 對此列提出異議
2025年12月16日 申報日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
處分(D)11,815——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
開啟申報文件 0001193125-25-322640 讀取自申報文件的XML 對此列提出異議

機構持有人(表格13F)

資料庫中沒有歸屬於該發行人的表格13F部位。尚未連結或尚未申報的持有人是缺漏,而不是零。

5%持有人(附表13D和13G)

此處讀取SEC結構化格式(2024年末起)提交的附表。更早的附表是自由文本,不予讀取。

5%持有人,最新事件在前,依申報
持有人占該類別比例持股數事件日期表格來源
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 申報日期:2025年12月19日SCHEDULE 13D/A第5號修訂開啟申報文件 0001104659-25-123157 對此列提出異議
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 申報日期:2025年12月19日SCHEDULE 13D/A第5號修訂開啟申報文件 0001104659-25-123157 對此列提出異議
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 申報日期:2025年12月19日SCHEDULE 13D/A第5號修訂開啟申報文件 0001104659-25-123157 對此列提出異議
Morgan Stanley Common Stock0.03111/30/2025 申報日期:2025年12月5日SCHEDULE 13G/A第1號修訂開啟申報文件 0000895421-25-000595 對此列提出異議
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 申報日期:2025年12月5日SCHEDULE 13G/A第1號修訂開啟申報文件 0000895421-25-000595 對此列提出異議
Klein Roger M. Common Stock, par value $0.0001 per share10.5163,000.0011/04/2025 申報日期:2025年11月12日SCHEDULE 13D開啟申報文件 0001651175-25-000007 對此列提出異議
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129,000.0011/04/2025 申報日期:2025年11月12日SCHEDULE 13D開啟申報文件 0001651175-25-000007 對此列提出異議
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申報日期:2025年11月4日SCHEDULE 13D/A第4號修訂開啟申報文件 0001104659-25-106048 對此列提出異議
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申報日期:2025年11月4日SCHEDULE 13D/A第4號修訂開啟申報文件 0001104659-25-106048 對此列提出異議
Mack Daniel Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申報日期:2025年11月4日SCHEDULE 13D/A第4號修訂開啟申報文件 0001104659-25-106048 對此列提出異議
Morgan Stanley Common Stock10.5163,71808/31/2025 申報日期:2025年9月8日SCHEDULE 13G開啟申報文件 0000895421-25-000528 對此列提出異議
Morgan Stanley Smith Barney LLC Common Stock10.5163,71808/31/2025 申報日期:2025年9月8日SCHEDULE 13G開啟申報文件 0000895421-25-000528 對此列提出異議

比例是申報文件所指類別的比例,由持有人自行陳述。團體成員各自申報團體的股份,因此各列不應相加。

已讀取的內容

已讀取2,102,727份申報文件,日期為2004年6月14日至2026年11月13日:表格3, 3/A, 4, 4/A, 5, 5/A。

檔案仍在讀取時,某些年份可能不完整。某年在此顯示的申報較少,並不表示實際提交得少。

依申報年份統計已讀取的文件
申報年份已讀取文件
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024195,705
2025235,520
2026254,737

SEC要求使用XML之前提交的文件只列出,不擷取內容。

返回Evoke Pharma Inc